XRCC1 and breast carcinoma: In addition, our analysis of data related to breast cancer patients harboring nonsynonymous somatic mutations in either gene of XRCC1-HRAS indicates poor survival rate compared with wild-type group (P = 0, log-rank test, S6E Fig).